Clovis Oncology Inc. Stock
Price
Target price
€0.077
€0.077
-6.090%
-
-6.090%
-
31.03.23 / Tradegate
WKN: A1JPJY / Symbol: CLVS / Name: Clovis Oncology / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Clovis Oncology Inc. Stock
Clovis Oncology Inc. took a tumble today and lost €0.000 (-6.090%).
Based on 2 Buy predictions and 1 Sell predictions the sentiment towards Clovis Oncology Inc. is rather balanced.
Our community identified positive and negative aspects for Clovis Oncology Inc. stock for the coming years. 2 users see the criterium "Shareholder structure" as a plus for the Clovis Oncology Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
Pros and Cons of Clovis Oncology Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Clovis Oncology Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Clovis Oncology Inc. | -6.090% | 0.000% | 0.000% | -95.821% | 0.000% | -98.668% | -99.821% |
| Sorrento Therapeutics Inc. | -24.520% | 0.000% | 0.000% | -86.746% | -65.296% | -83.166% | - |
| Evolus Inc | 1.960% | 1.961% | -5.455% | -26.415% | 10.638% | 103.125% | - |
| Hepion Pharmaceuticals Inc. | 1.850% | 13.615% | -12.460% | -39.283% | 161.013% | -53.529% | - |
Comments
News
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis
